NephroGenex Inc

NephroGenex — Investor Presentation (April 2014)

22 slides from NephroGenex's investor presentation, Apr 9, 2014

  1. Slide 1: Company Overview April 2014

    Company Overview April 2014 April 2012

  2. Slide 2: Forward-looking statements

    This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “m

  3. Slide 3: The NephroGenex Pipeline

    The NephroGenex Pipeline Clinical Program / Indication Preclinical Phase I Phase II Phase III Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy IV PYRIDORIN ® Acute Kidney Injury Clinical Program Oral BID 300 mg tablet targets pathogenic oxidative chemistries 2015 IV formulation for

  4. Slide 4: Corporate Overview

    Corporate Overview Late-stage company targeting pathogenic oxidative chemistries to treat kidney disease Oral Pyridorin (Phase 3) – to slow progression of diabetic nephropathy (DN) IV Pyridorin (Preclinical) – to treat acute kidney injury (AKI) Oral Pyridorin for DN is in Phase 3 of Development. It

  5. Slide 5: The NephroGenex Team

    The NephroGenex Team Board of Directors Member Affiliation, Position Pierre Legault NephroGenex, Director J. Wesley Fox, Ph.D. NephroGenex, Director Robert Seltzer Care Capital, Director Eugen Steiner, M.D. BioStratum, Director Martin Vogelbaum Rho Ventures, Director Jim Mitchum Director & Chairman

  6. Slide 6: Oral Pyridorin for Diabetic Nephropathy Overview

    Oral Pyridorin for Diabetic Nephropathy Overview 6 6

  7. Slide 7: Oral Pyridorin Market Potential

    Oral Pyridorin Market Potential 7 DN patients progress from high risk, to early stage (microalbuminuria), to overt nephropathy (macroalbuminuria), to end-stage-renal-disease (ESRD) and dialysis 19 M diagnosed diabetics in the US, of which 33% (6.3 M) exhibit kidney disease 2.8 M macroalbuminuria (ov

  8. Slide 8: Pyridorin targets oxidative chemistries underlying diabetic nephropathy

    Hyperglycemia increases pathogenic oxidative chemistries* Elevated levels of oxidative chemistries promote the development and progression of DN* Pyridorin targets oxidative chemistries, a key underlying cause of DN DN is the leading cause of dialysis and chronic kidney failure Pyridorin is an effec

  9. Slide 9: Phase 2a PYR-205/207 results

    Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Pyridorin Treatment Effect P value All Patients 57, 27 1.75 0.64 1.96 0.86 0.11 0.26 0.34 0.92 68% 0.0322 Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increa

  10. Slide 10: Phase 2b PYR-210 treatment effect in standard of care patients

    Patients on established (or stable) standard of care (SOC) at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAL patient population Patient not on SOC at screening exhibited higher initial blood pressures, more frequent medication changes, and drops in

  11. Slide 11: PIONEER Trials Timeline

    PIONEER Trials Timeline Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2014 2015 2016 Secured CRO (Collaborative Study Group & Medpace) Expect first patient to enter PIONEER pivotal Phase 3 trial June 2014 Publication on new end point Expect completion TQT cardiac safety study Dec 2014 Anticipate EMA acceptanc

  12. Slide 12: Phase 3 PIONEER trial design

    Objective: Evaluate safety efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population Type 2 diabetic nephropathy patients Baseline SCr from 1.3 to 3.0 mg/dL Patients must be on an establis

  13. Slide 13: Exclusivity: Patents and New Chemical Entity

    Exclusivity Patents and New Chemical Entity (NCE) Japan . Post marketing surveillance system provides exclusivity for up to 8 years (NCE 8 years exclusivity) Method of use (patient population), manufacturing and new chemical entity (NCE) status: U.S. . September 2028 including patent extension – dos

  14. Slide 14: Corporate Summary

    Corporate Summary Experienced management team focused on clinical success Diabetic nephropathy represents a large and growing unmet need Oral Pyridorin could potentially treat as many as 10 M patients, more than half of the diabetic population in the US No FDA approved alternative treatments for DN

  15. Slide 15: Appendix

    @Nephrogenex Appendix

  16. Slide 16: Pyridorin Mechanism of Action

    Pyridorin Mechanism of Action O2/Mn+ Protein Protein Protein Schiff base O2/Mn+ O2/Mn+ Reactive carbonyl species MGO & 3-DG and ROS O2/Mn+ Protein Protein Amadori A.G.E. Protein A.G.E. Glucose Toxic carbonyl compounds Advanced glycation end-products ROS - Reactive oxygen species Advanced glycation e

  17. Slide 17: Pyridorin Phase 2a Program PYR-206

    Multi-center, randomized, double-blind, placebo-controlled trial Number of centers: 46 Location of centers: U.S. Dose: 50mg BID x 24 weeks Study objectives: assess safety, tolerability and biological activity Diabetic patients with DN due to type 1 or type 2 diabetes N = 128 (65 treated, 63 placebo)

  18. Slide 18: Clinical Results PYR-206: Mild to Moderate Diabetic Nephropathy

    Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Pyridorin Treatment Effect P value All Patients 65, 63 1.27 0.34 1.33 0.38 0.12 0.40 0.16 0.28 27% 0.2426 Type 2 Diabetes 40, 40 1.2

  19. Slide 19: Clinical Results PYR-205/207: Moderate to Advanced Diabetic Nephropathy

    Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Pyridorin Treatment Effect P value All Patients 57, 27 1.75 0.64 1.96 0.86 0.11 0.26 0.34 0.92 68% 0.0322 Type 2 Diabetes 45, 2

  20. Slide 20: Clinical Results PYR-210

    Clinical Results PYR-210 Patient Population Dose Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Pyridorin Treatment Effect P value Patients NOT on SOC at screening3 Pre-specified analysis 300 mg 36, 34 2.32 0.50 2.34 0.67 0.62 0.75 0.31 0.68 n/a n/a 150

  21. Slide 21: IV Pyridorin Rationale for Acute Kidney Injury

    Pyridorin targets specific pathogenic oxidative chemistries that emerge in diabetes These pathogenic oxidative chemistries also emerge in acute kidney injury caused by: Reperfusion injury in CV surgery Contrast media in angiography Severe AKI may result in acute renal failure (ARF) IV Pyridorin Rati

  22. Slide 22: Safety Conclusions

    Safety Conclusions There were no meaningful differences between groups in AEs There was possibly an increase in diarrhea & constipation with the higher Pyridorin 300 mg bid dose Diarrhea: Placebo = 6%, 150 mg = 3%, 300 mg = 11 % Constipation: Placebo = 4%, 150 mg = 4%, 300 mg = 10 % There were no di

NephroGenex — Investor Presentation (April 2014) on 6ix